Long-Term Treatment of Central Precocious Puberty with a Long-Acting Analogue of Luteinizing Hormone-Releasing Hormone. Effects on Somatic Growth and Skeletal Maturation

1984 ◽  
Vol 39 (9) ◽  
pp. 591-592
Author(s):  
M. JOAN MANSFIELD ◽  
DONNA E. BEARDSWORTH ◽  
JACQUELYN S. LOUGHLIN ◽  
JOHN D. CRAWFORD ◽  
HANS H. BODE ◽  
...  
1983 ◽  
Vol 309 (21) ◽  
pp. 1286-1290 ◽  
Author(s):  
M.Joan Mansfield ◽  
Donna E. Beardsworth ◽  
Jacquelyn S. Loughlin ◽  
John D. Crawford ◽  
Hans H. Bode ◽  
...  

1989 ◽  
Vol 142 (5) ◽  
pp. 1235-1238 ◽  
Author(s):  
Andrea U. Decensi ◽  
Domenico Guarneri ◽  
Paola Marroni ◽  
Liborio Di Cristina ◽  
Michela Paganuzzi ◽  
...  

1984 ◽  
Vol 62 (7) ◽  
pp. 853-855 ◽  
Author(s):  
Kathleen M. Landymore ◽  
Michael Wilkinson

Luteinizing hormone-releasing hormone (LHRH) agonist analogs have been suggested as a useful treatment for precocious puberty, though there is some concern that long-term treatment might be deleterious to normal sexual development. We have taken advantage of the very short maturation period of the female rat (approximately 35 days from birth) to examine the effects of chronic (daily) treatment with [D-Ala6, des Gly-[Formula: see text]]-LHRH ethylamide. We have observed that this treatment (either 1 or 2 μg/day) from day 5 after birth significantly delays sexual maturation but does not affect subsequent sexual cycles.


Sign in / Sign up

Export Citation Format

Share Document